Stock IMCR IMMUNOCORE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
48.98 USD +4.86% Intraday chart for Immunocore Holdings plc +2.08% -28.31%
May. 29 Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3 MT
May. 29 Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
GL
Immunocore to present at the Jefferies Global Healthcare Conference
GL
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3
MT
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
GL
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma
CI
Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director
CI
Mizuho Cuts Price Target on Immunocore to $88 From $90, Keeps Buy Rating
MT
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens
MT
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS Reports Q1 Revenue $70.5M
MT
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Immunocore reports first quarter financial results and provides a business update
GL
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group
AQ
Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target
MT
Immunocore announces upcoming presentation and posters at ASCO 2024
GL
Immunocore to present at upcoming investor conferences
GL
Immunocore Holdings Files Mixed-Securities Shelf Registration
MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM
Immunocore presented two posters at CROI 2024
GL
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating
MT
Immunocore to present at upcoming investor conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMCR Stock
  4. News Immunocore Holdings plc